Edition:
United States

Bionomics Ltd (BNO.AX)

BNO.AX on Australia Stock Exchange

0.35AUD
21 Apr 2017
Change (% chg)

$0.01 (+2.17%)
Prev Close
$0.34
Open
$0.35
Day's High
$0.35
Day's Low
$0.34
Volume
55,845
Avg. Vol
355,336
52-wk High
$0.50
52-wk Low
$0.23

Latest Key Developments (Source: Significant Developments)

Bionomics says chairman Graeme Kaufman will retire at the end of August 2016
Monday, 8 Aug 2016 11:39pm EDT 

Bionomics Ltd : Says chairman Graeme Kaufman will retire at the end of August 2016 . Appoints Errol De Souza as chairman .  Full Article

Bionomics announces extension of strategic collaboration with Merck & Co., Inc
Wednesday, 7 Oct 2015 05:55pm EDT 

Bionomics:Extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.Merck &Co., Inc. to make $9 million investment in Bionomics.Separately, Merck & Co., will also purchase 21,659,230 million ordinary shares at A$0.5938, a 29% premium to Bionomics' closing price on 7 October 2015.  Full Article

Bionomics reports positive data from phase 1 multiple ascending dose trial of BNC210 for anxiety and depression
Wednesday, 16 Sep 2015 06:00am EDT 

Bionomics Limited:Reports positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor being developed for the treatment of anxiety & depression.Says the results showed that BNC210 was safe and well-tolerated, and consistent with its mechanism of action at the *7 receptor, showed that BNC210 significantly reduced the effect of nicotine as measured by electrocephalogram.  Full Article

Bionomics Limited announces issue of shares
Thursday, 18 Jun 2015 01:33am EDT 

Bionomics Limited:Issues 35,500 fully paid ordinary shares.  Full Article

Bionomics Ltd files patent for use of BNC105 in combination with PD-1 And CTLA-4 Immuno-oncology antibodies
Monday, 15 Jun 2015 06:00am EDT 

Bionomics Ltd:Filed a patent application covering use of BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer.This new patent is based on important preclinical findings regarding the synergistic effects in preclinical models of a combination of the company's proprietary novel oncology compound BNC105 and antibodies against known immuno-oncology targets.  Full Article

More From Around the Web

BRIEF-Cover-More updates on Zurich Travel Solutions Pty Ltd's offer

* Foreign Investment Review Board provided written notice that commonwealth has no objections to Zurich Travel Solutions Pty Limited's offer